Structure Therapeutics
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various ch...
Latest News
7 days ago · globenewswire.com
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsPhase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies Reported Phase 1 SAD data for ACCG-2671 (oral small molecule amylin receptor agonist),demonstrating a ~6-day half-life and no serious adverse events; MAD clinical trial dosing underway, with topline data expected in 1H 2027 Cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026expected to fund projected operations and key clinical milestones through 2028 SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2026, and provided a business update across its oral small molecule obesity portfolio. “With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management,” said Raymond Stevens, Ph.D.
8 days ago · zacks.com
Novo Up 4% in a Month: How Should Investors Approach the Stock Now?NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.
28 days ago · globenewswire.com
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD. Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension Date/Time: November 15, 2026, 2:30 p.m.
1 month ago · zacks.com
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
2 months ago · seekingalpha.com
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptStructure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · seekingalpha.com
Structure Therapeutics: The Amylin Data Changes The MathStructure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug, aleniglipron. Aleniglipron's 72-week open-label data showed 16.2% weight loss, low AE discontinuations, and no DILI, though Phase 3 efficacy and safety monitoring remain key. ACCG-2671, an oral amylin agonist, now has human data and offers potential for combination therapy, further differentiating GPCR's pipeline.
2 months ago · seekingalpha.com
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management TranscriptStructure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
3 months ago · seekingalpha.com
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long TermSepterna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, with $26.7m Q2 collaboration revenue and a new R&D program initiated. SEP-479, an oral small molecule for hypoparathyroidism, is a differentiated asset with a pivotal Q1 2027 data readout as a key catalyst.
5 months ago · seekingalpha.com
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptStructure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
5 months ago · reuters.com
Structure's experimental obesity pill shows no signs of liver injuryStructure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients continued to lose weight even on the lower doses of the drug.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove GPCR